Disease Detail

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
FGFR3-TACC3 AZD4547 cervical squamous cell carcinoma predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT01351103 Phase I LGK974 LGK974 + Spartalizumab A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands Recruiting
NCT02187848 Phase Ib/II SAR408701 Evaluation of SAR408701 in Patients With Advanced Solid Tumors Recruiting
NCT02257528 Phase II Nivolumab Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer Active, not recruiting
NCT02348398 Phase II Pazopanib + Topotecan Phase II Study of Pazopanib and Topotecan in Cervical Cancer Withdrawn
NCT02558348 Phase Ib/II Anlotinib Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001) Unknown status
NCT02584478 Phase Ib/II Anlotinib + Carboplatin + Paclitaxel Phase 1/2a Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002) Recruiting
NCT02646319 Phase I Nab-Rapamycin Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations Completed
NCT02834013 Phase 0 Ipilimumab + Nivolumab Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting
NCT02853604 Phase III ADXS11-001 Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer (AIM2CERV) Active, not recruiting
NCT03108495 Phase II LN-145 Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma Recruiting
NCT03357757 Phase II Avelumab + Valproic acid Avelumab With Valproic Acid in Virus-associated Cancer (LATENT) Recruiting
NCT03367871 Phase II Cisplatin + Paclitaxel + Pembrolizumab Combination Pembrolizumab, Paclitaxel and Cisplatin in Patients With Cervical Cancer Recruiting
NCT03438396 Phase II Tisotumab Vedotin A Trial of Tisotumab Vedotin in Cervical Cancer Active, not recruiting
NCT03635567 Phase III Bevacizumab + Carboplatin + Paclitaxel Bevacizumab + Cisplatin + Paclitaxel Carboplatin + Paclitaxel Cisplatin + Paclitaxel Cisplatin + Paclitaxel + Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Bevacizumab + Carboplatin + Paclitaxel + Pembrolizumab Bevacizumab + Cisplatin + Paclitaxel + Pembrolizumab Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826) Recruiting
NCT03738228 Phase I Atezolizumab + Cisplatin Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer Recruiting
NCT03786081 Phase Ib/II Bevacizumab + Tisotumab Vedotin Carboplatin + Tisotumab Vedotin Pembrolizumab + Tisotumab Vedotin Safety and Efficacy of Tisotumab Vedotin in Combination With Other Cancer Agents in Subjects With Cervical Cancer Recruiting
NCT03830866 Phase III Durvalumab Cisplatin + Durvalumab Carboplatin + Durvalumab Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA) (CALLA) Recruiting